MET and Hypoalbuminemia: Edema and hypoalbuminemia are known side effects of HGF/c-Met inhibitors, including ficlatuzumab.20-22 In a prior monotherapy study of ficlatuzumab, serum albumin levels decreased in all patients to below the lower limit of normal by study completion.